-
-
Nardino RJ. Chitosan for weight loss and cholesterol lowering. Altern Med Alert 2003;6(1):5-8.
-
Effects of Losartan on Cardiovascular Morbidity and Mortality in
Patients with Isolated Systolic Hypertension and LVH; Increase in
Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1
Diabetes; HRT, Lipid, and Glucose Metabolism in Diabetic and
Nondiabetic Postmenopausal Women; Effects of Long-Term Treatment With
ACE Inhibitors in the Presence or Absence of Aspirin; Long-Term Risks
Associated with Atrial Fibrillation: 20-Year Follow-up of the
Renfrew/Paisley Study; Olfactory Impairment in Older Adults
-
FDA Approves Claritin For OTC Use For Seasonal Rhinitis; Simpler Atrial Fibrillation Management; Oral Anticoagulation Vs Aspirin in AF; Immunization Does Not Cause Autism; Statins May Lower CRP Levels; Simvastatin Reduced CRP Plasma Levels; FDA Actions
-
Aripiprazole (Abilify), a new drug for schizophrenia, received FDA approval November 15; on November 14, Neurocrine Biosciences Inc. announced positive results from its first phase III clinical trial with indiplon-IR achieving primary and secondary end points of sleep initiation.
-
The results of 3 recent investigations suggest that immunotherapy still has the potential to become a treatment for AD but that the road to its successful development is likely to be a long one.
-
In this thoughtful, well-balanced review, Clarke and Guttman review the evidence for using new dopamine agonists to treat patients with early PD.
-
The Adult AIDS Clinical Trials Group (AACTG) has responded to research showing a link between HIV antiretroviral treatment and meta-bolic disorders with guidelines that offer recommendations for assessing, monitoring, and treating the problem.
-
While the exact cause remains to be found, it is no longer a mystery whether certain antiretroviral drugs can lead to metabolic changes associated with heart disease.
-
While there are some similarities between HIV and tuberculosis (TB) treatments, its the differences in treatment regimens, duration, and end results that have made HIV clinicians and others somewhat hesitant to use the directly observed treatment (DOT) strategy, which has been so successful in treating TB, with HIV patients.